Navigation Links
Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
Date:10/22/2010

BALTIMORE, Oct. 22 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore.  In addition, more results from the second trial (CF302) have been released to supplement the top line results reported on 22nd June 2010.

The two studies were of similar design and encompass 643 patients from 11 countries.  Over the 26 weeks of the two studies, patients treated with Bronchitol had an average 7.3% improvement in lung function (FEV1) compared to baseline (p<0.001) and a highly significant improvement compared to patients in the control group (p<0.001).  In the sub group of patients who were also on rhDNase, patients taking Bronchitol showed a 5.3% improvement from baseline (p<0.001), that was again superior to the control group (p=0.020).  In the sub group of patients who were not on rhDNase, patients taking Bronchitol showed a 9.44% improvement from baseline (p<0.001), that was also superior to the control group (p=0.009).  The overall rate per annum reduction in exacerbations for patients on Bronchitol versus those on control was 25% (NS) and the number of patients experiencing an exacerbation was 29% lower for those taking Bronchitol (NS). This result was achieved in a well treated patient population who overall had a very low rate of exacerbations in the study.

"This comprehensive analysis of the pooled results provides an important insight into the overall benefits Bronchitol can provide to patients who are receiving current best standard of care," said Pharmaxis Chief Executive Officer Dr. Alan Robertson.  "The number of exacerbations in the two studies was fairly low, reflecting the aggres
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
2. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
3. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
4. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
5. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
6. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
7. Pharmaxis Establishes Named Patient Program for Bronchitol
8. Pharmaxis Long-Term Safety Study of Bronchitol Completes
9. Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent
10. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
11. Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 29, 2014 Electrodes ... potential which can be amplified to diagnose as ... electrodes used in medical devices facilitate the detection ... from muscle cells and neurons of the patients. ... utilize the radiofrequency alternating current to perform minimally ...
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... growth through 2013 with the introduction of new ... well-covered in Vaccines: The World Market. The Kalorama ... covering specifically commercialized vaccines and developmental vaccines for ... not only individuals, but also entire communities from ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... (Nasdaq: UPI ), a medical device company ... treat voiding dysfunctions, announced today that David Kaysen, Uroplasty,s ... and CFO, will present the Company,s business strategy and ... Conference at 3:30  PM PDT on Tuesday, August 17, ...
... SPRING, Md., Aug. 16 The U.S. Food ... of the drug midodrine hydrochloride, used to treat ... required post-approval studies that verify the clinical benefit ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2FDA Proposes Withdrawal of Low Blood Pressure Drug 2FDA Proposes Withdrawal of Low Blood Pressure Drug 3
(Date:10/30/2014)... the DFG Research Center for Regenerative Therapies Dresden - ... for the first time the in vitro growth of ... mouse embryonic stem cells. Correct spatial organization of motor ... was observed., This study has been published online by ... on 30.10.2014 ., For many years Elly Tanaka and ...
(Date:10/30/2014)... Beach, Florida (PRWEB) October 30, 2014 ... Halloween visit to Pompano Beach firefighters, showing that you ... community. , Timothy met firefighters Tracey and Carl ... by Galuppi’s Restaurant and the Pompano Beach Chamber of ... outside the fire truck, letting Timothy wear his real ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager focused ... people save money through its innovative discount card program. ... in the new health care system, the Paramount Rx ... relationship between consumers, businesses and the pharmacy industry. ... today with medical costs is the rising price of ...
(Date:10/30/2014)... By Tara Haelle ... (HealthDay News) -- More than 100 genes have been ... new studies report. And researchers say they are ... overall that may contribute to the disorder. Autism ... by communication and social difficulties and repetitive behaviors. An ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... , CAMBRIDGE, Mass. , ... organization focused on advancing human health through innovation, today ... Business Innovation Research (SBIR) contract from the National Aeronautics ... develop nanoscale diagnostic technologies that facilitate whole health analysis ...
... from mice, scientists from Iowa and Iran have discovered a ... to be rejected by a recipient,s immune system. This strategy, ... 2010 print issue of The FASEB Journal ( ... cells. Once fused, the hybrid cells have DNA from both ...
... produces an extraordinary and dangerous poison. This is the only ... A study carried out at the University of Haifa has ... Has the almond tree developed a unique way of ... of Environmental and Evolutionary Biology and the Department of Science ...
... the process of diagnosing heart conditions. The portable ... with funding from the Engineering and Physical Sciences Research ... to its unprecedented sensitivity to magnetic fluctuations the device ... including heart problems in foetuses, earlier than currently available ...
... ... and downs of the decade. , ... Pennington, NJ (PRWEB) January 28, 2010 -- In good times and in bad, people ... Robinson, Inc., overall attitudes towards Super Bowl advertising have remained strongly positive throughout the economic ...
... 2010 ... information, many more products in an ever expanding market but “simplified buying for the ... ... -- 2010 marks the launch of Décor Grille’s new “ Security Direct ” web ...
Cached Medicine News:Health News:NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR 2Health News:Stem cell breakthrough: Bone marrow cells are the answer 2Health News:The almond tree's secret weapon 2Health News:The almond tree's secret weapon 3Health News:Breakthrough heart scanner will allow earlier diagnosis 2Health News:Super Bowl Advertising, In Good Times And Bad 2Health News:Super Bowl Advertising, In Good Times And Bad 3Health News:Dcor Grille Leads into the Next Decade with its New Security Web Site 2
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: